within Pharmacolibrary.Drugs.C_CardiovascularSystem.C01C_CardiacStimulantsExclCardiacGlycosides.C01CA27_Droxidopa;

model Droxidopa
  extends Pharmacolibrary.Drugs.ATC.C.C01CA27;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>C01CA27</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Droxidopa is a synthetic amino acid precursor of norepinephrine. It is used as a prodrug to increase norepinephrine concentrations, primarily for the treatment of neurogenic orthostatic hypotension in patients with Parkinson’s disease, multiple system atrophy, pure autonomic failure, dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy. It is currently approved for use in several countries, including the United States.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for oral droxidopa use in adults with neurogenic orthostatic hypotension; general adult population with normal hepatic and renal function.</p><h4>References</h4><ol><li><p>Chen, JJ, &amp; Hewitt, LA (2018). Comparison of the Pharmacokinetics of Droxidopa After Dosing in the Fed Versus Fasted State and with 3-Times-Daily Dosing in Healthy Elderly Subjects. <i>Drugs in R&amp;D</i> 18(1) 77–86. DOI:<a href=\"https://doi.org/10.1007/s40268-018-0226-z\">10.1007/s40268-018-0226-z</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29392574/\">https://pubmed.ncbi.nlm.nih.gov/29392574</a></p></li><li><p>Quinn, NP (1984). Anti-parkinsonian drugs today. <i>Drugs</i> 28(3) 236–262. DOI:<a href=\"https://doi.org/10.2165/00003495-198428030-00002\">10.2165/00003495-198428030-00002</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/6435991/\">https://pubmed.ncbi.nlm.nih.gov/6435991</a></p></li><li><p>Iida, N, Tsubakihara, Y, Shirai, D, Imada, A, &amp; Suzuki, M (1994). Treatment of dialysis-induced hypotension with L-threo-3,4-dihydroxyphenylserine. <i>Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association</i> 9(8) 1130–1135. DOI:<a href=\"https://doi.org/10.1093/ndt/9.8.1130\">10.1093/ndt/9.8.1130</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/7800213/\">https://pubmed.ncbi.nlm.nih.gov/7800213</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Droxidopa;
